Arthritis, Psoriatic
-
Subject Areas on Research
- A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.
- Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.
- Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis.
- Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.
- Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11.
- Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.
- Infliximab treatment for rheumatic disease: clinical and radiological efficacy.
- International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.
- Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting.
- PSORS2 is due to mutations in CARD14.
- Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting.
- Proceedings of the GRAPPA 2016 Retreat.
- Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.
- Psoriatic arthritis of the foot and ankle: analysis of joint involvement and diagnostic errors.
- Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria.
- Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting.
- Retinal venular calibre is increased in patients with autoimmune rheumatic disease: a case-control study.
- Secukinumab (AIN-457) for the treatment of Psoriasis.
- Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting.
- The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting.
- Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.